Aducanumab: What the FDA Approval Means for Clinicians
The Carlat Geriatric Psychiatry Report, Volume 1, Number 1&2, January 2022
https://www.thecarlatreport.com/newsletter-issue/cgprv1n12/
Issue Links: Learning Objectives
Andrew Budson, MD
Chief of Cognitive and Behavioral Neurology at the VA Boston Healthcare System; Associate Director and Leader of Education at Boston University Alzheimer’s Disease Research Center; Lecturer at Harvard Medical School.
Dr. Budson discloses that his lab received research funding from Biogen, the manufacturer of aducanumab, in 2020. The funds were received by the Veterans Affairs Boston Health Care System and did not contribute to his salary. He also received funds for a one-day consultation meeting with Sage Pharmaceuticals (manufacturer of the antidepressant brexanolone) in February 2020. Dr. Carlat has reviewed the content of this interview and determined that there is no commercial bias as a result of these financial relationships.
Aducanumab (Aduhelm), which is given intravenously once a month, is a monoclonal antibody directed against amyloid plaques that are associated with Alzheimer’s disease. The idea is that aducanumab will stick to the plaques in the brain. Once there’s an antibody on a plaque, the immune system signals the body’s defense mechanisms to remove it.
You can't view details of this content, please login or buy subscription here